Director, US HIV Prevention (PrEP) Forecasting at Gilead Sciences

Foster City, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Bachelor's Degree and Twelve Years’ Experience OR Master's Degree and Ten Years’ Experience
Broad and deep skill set including functional expertise, therapeutic area knowledge (HIV PrEP), communication skills, leadership and influencing, executive presence

Responsibilities

Responsible for demand forecasting across brands in the US HIV PrEP business (including daily and long-acting oral(s) and long acting injectable(s)) as well as monthly Actual vs Forecast (AvF) reporting
Lead and deliver Gilead’s quarterly Latest Estimate (LE) forecasting for US HIV PrEP, including developing forecast scenario analyses, highlighting key risks and opportunities to characterize forecast uncertainties and critical drivers for executive leadership
Developing forecast scenario analyses, including key risks and opportunities, to characterize forecast uncertainties and key drivers for executive leadership
Support the preparation of the quarterly CCO Binder and earnings deliverables for HIV PrEP with the Executive Director
Analyze secondary data sources (script data like IQVIA, audit data like Ipsos, epidemiology data like NHANES, claims data, etc.) to glean insights and understand implications for our business, inform our strategies, and make actionable recommendations
Collaborate within HIV Integrated Insights on key forecast inputs, including market research commercial analytics, and with cross-functional partners, including US sales analytics/field-force assumptions and our Global forecasting and analytics colleagues
Regularly communicate with senior executives and strategic partners to report analytical findings and projections related to forecasting, inventory management, and essential performance metrics/diagnostics
Lead performance reporting and diagnostics, including design and implementation of HQ facing dashboards and reports
Seek and implement opportunities to streamline and improve business operations and technical capabilities of the organization while identifying opportunities to drive forecasting innovation and performance

Skills

Forecasting

HIV Prevention

PrEP

Leadership

Stakeholder Management

Therapeutic Area Knowledge

Communication

Influencing

Executive Presence

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free